Abstract
Diabetic retinopathy is a common and devastating microvascular complication in diabetes and is a leading cause of acquired blindness among the people of occupational age. Recent large landmark clinical studies have shown that intensive control of blood glucose or blood pressure (BP) reduces the risk for diabetic retinopathy. However, the strict control of blood glucose or BP is often difficult to maintain. Further, current therapeutic options for the treatment of sightthreatening proliferative diabetic retinopathy (PDR) such as photocoagulation and vitrectomy are limited by considerable side effects and far from satisfactory. Therefore, to develop novel therapeutic strategies that specifically target PDR is actually desired for most patients with diabetes. Although various biochemical and hemodynamic pathways are implicated in the diabetic retinopathy, recent clinical study has substantiated the concept of “metabolic memory”, and suggested the active involvement of advanced glycation end products (AGEs) and oxidative stress in this sight-threatening disorder. We, along with others, have recently found that pigment epithelium-derived factor (PEDF), a glycoprotein with complex neuroprotective, anti-angiogenic, anti-oxidative, and anti-inflammatory properties, could potentially be exploited as a therapeutic option for the treatment of diabetic retinopathy. Therefore, this article summarizes the role of AGEs and oxidative stress in diabetic retinopathy and discusses a potential utility of the blockade of this system by PEDF in this devastating disorder.
Keywords: Diabetic retinopathy, AGEs, oxidative stress, RAGE, PEDF
Current Pharmaceutical Biotechnology
Title: Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy
Volume: 12 Issue: 3
Author(s): Sho-ichi Yamagishi and Takanori Matsui
Affiliation:
Keywords: Diabetic retinopathy, AGEs, oxidative stress, RAGE, PEDF
Abstract: Diabetic retinopathy is a common and devastating microvascular complication in diabetes and is a leading cause of acquired blindness among the people of occupational age. Recent large landmark clinical studies have shown that intensive control of blood glucose or blood pressure (BP) reduces the risk for diabetic retinopathy. However, the strict control of blood glucose or BP is often difficult to maintain. Further, current therapeutic options for the treatment of sightthreatening proliferative diabetic retinopathy (PDR) such as photocoagulation and vitrectomy are limited by considerable side effects and far from satisfactory. Therefore, to develop novel therapeutic strategies that specifically target PDR is actually desired for most patients with diabetes. Although various biochemical and hemodynamic pathways are implicated in the diabetic retinopathy, recent clinical study has substantiated the concept of “metabolic memory”, and suggested the active involvement of advanced glycation end products (AGEs) and oxidative stress in this sight-threatening disorder. We, along with others, have recently found that pigment epithelium-derived factor (PEDF), a glycoprotein with complex neuroprotective, anti-angiogenic, anti-oxidative, and anti-inflammatory properties, could potentially be exploited as a therapeutic option for the treatment of diabetic retinopathy. Therefore, this article summarizes the role of AGEs and oxidative stress in diabetic retinopathy and discusses a potential utility of the blockade of this system by PEDF in this devastating disorder.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi and Matsui Takanori, Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy, Current Pharmaceutical Biotechnology 2011; 12 (3) . https://dx.doi.org/10.2174/138920111794480534
DOI https://dx.doi.org/10.2174/138920111794480534 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Polyphenols can Potentially Prevent Atherosclerosis and Cardiovascular Disease by Modulating Macrophage Cholesterol Metabolism
Current Molecular Pharmacology Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Female Infertility and Cardiovascular Risk - A Hype or an Underestimated Reality?
Current Pharmaceutical Design Novel Strategies for Preventing Diabetes and Obesity Complications with Natural Polyphenols
Current Medicinal Chemistry The Obligatory Role of the Acetylcholine-Induced Endothelium-Dependent Contraction in Hypertension: Can Arachidonic Acid Resolve this Inflammation?
Current Pharmaceutical Design Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Novel Mutation of the NOTCH3 Gene in a Chinese Pedigree with CADASIL
CNS & Neurological Disorders - Drug Targets Inspired Nitric Oxide and Modulation of Oxidative Stress During Cardiac Surgery
Current Drug Safety Rationale of Statin Therapy in Septic Patients
Current Vascular Pharmacology The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry CYLD-Mediated Signaling and Diseases
Current Drug Targets Modulation of Collagen Turnover in Cardiovascular Disease
Current Pharmaceutical Design Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews Genomic Variations Affecting Biological Effects of Statins
Current Drug Metabolism Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology Adonis sp., Convallaria sp., Strophanthus sp., Thevetia sp., and Leonurus sp. - Cardiotonic Plants with Known Traditional Use and a Few Preclinical and Clinical Studies
Current Pharmaceutical Design ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Dual Inhibitors of β-Amyloid Aggregation and Acetylcholinesterase as Multi-Target Anti-Alzheimer Drug Candidates
Current Topics in Medicinal Chemistry